Spotter · Intent-Driven · Evidence-Backed

Ask one question. BioSniper reads the biotech company for you.

Spotter reads your intent, picks the right Agents, pulls evidence from 7 sources, and hands back a cited summary, risks, and next steps.

SECFDACT.govPubMedPatentsNewsMarket

Tell Spotter what to verify.

One line in — Spotter orchestrates the Agents and returns cited judgments.

Auto-Extract

Spotter reads SEC & FDA filings for you

Never Miss

PDUFA dates & catalyst tracking

Evidence-Based

Cross-verified with citations

7 Sources · 24/7

1,000+ companies tracked

Biotech Pulse

Live market · upcoming catalysts · curated insights — all at a glance.

XBI

$129.83+1.62%

IBB

$167.50+1.97%

New Trials Initiated

4,376

FDA Approvals

395

Partnership Deals

19,806

Phase 3 Completion

31%

1,513 Companies16,187 Trials90,284 SEC Filings55,684 PubMedUpdated 6/4/2026

Recent M&A

2026-06-01collaboration: darovasertib - Collaboration for the development of darovasertib in combination with crizotinib for metastatic uveal melanoma.
2026-05-31merger: Avenzo Therapeutics, Inc. - Rallybio Corporation entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics, Inc., a clinical-stage biotechnology company developing next-generation oncology therapies.
2026-05-29licensing: SPY003 - Amendment to the SPY003 License Agreement expanding the field of use for SPY003 to all therapeutic, prophylactic, palliative and diagnostic uses, subject to specific dosing restrictions.

Upcoming Catalysts

Jun 5
PDUFA
ARVNPDUFA Date: vepdegestrant
Jun 9
Phase3 Topline
NVOPhase 3 Topline: ZEUS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Establ
Jun 15
Phase3 Topline
RPRXPhase 3 Topline: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Aveluma
Jun 15
Phase3 Topline
GHRSPhase 3 Topline: S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell P
Jun 16
Phase3 Topline
SNYNFPhase 3 Topline: A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of an Omicron JN.1
Jun 17
Phase3 Topline
MLTXPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy
Jun 17
Phase3 Topline
MLTXPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy
Jun 19
Phase3 Topline
AZNPhase 3 Topline: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Inves
View Full Calendar
Upgrade for full details